Launching the US campaign in 2007, Movember raised $740,568 for the Prostate Cancer Foundation (PCF).

Funds raised through Movember are made directly to the PCF who are using the funds for high-impact research to find better treatments and a cure for prostate cancer. 

We are pleased to announce that the $740,568 raised by American Mo Bros and Mo Sistas will fund a variety of research projects focused on discovering new treatments for recurring prostate cancer.  These programs include:

Progression Biomarkers

Lead Investigator: Dr. Daniel Haber

Massachusetts General Hospital

The discovery of biomarkers that predict disease progression, or provide a signal for effectiveness of an experimental medication for prostate cancer, is a priority for PCF.  These markers will increase the pace of new medication development and signal physicians ealier when prostate cancer is progressing.  Dr. Haber, in collaboration with oncologists, biologists, and engineers, will refine a system that measures tumor cells in patient blood.  Molecular evaluation of circulating cells will be performed to better optimize prostate cancer therapy for individuals.

ETS Gene Fusions

Lead Investigators: Dr. Levi A. Garraway, Dana-Farber Cancer Institute, Broad Institute; Dr. Todd R. Golub, Broad Institute of Harvard and MIT; Dr. William C. Hahn, Dana-Farber Cancer Institute, Broad Institute

Scientists recently discovered that a specific genetic rearrangement in normal prostate cells leads to the production of cancer promoting factors (ETS factors) and prostate cancer.  It is presumed that discovery of medications that block the activity of ETS factors will arrest the growth of prostate cancer.  Dr. Golub will apply state-of-the-art genetic biotechnologies in a significant drug discovery effort to target ETS factors produced by prostate cancer cells.  Collaborators and the Broad Institute of Harvard and MIT will work with biologists and oncologists at the Dana-Farber Cancer Institute and Harvard Medical School to evaluate ETS factor inhibitors discovered in this work, and ultimately develop an experimental medication for prostate cancer patients.

Nutrition, Metabolism, & Patient Quality of Life

Lead Investigator: Dr. Matthew R. Smith

Massachusetts General Hospital Cancer Center

The best available treatment for advanced prostate cancer is the removal of testosterone hormones (angrogens) that drive the growth and progression of prostate cancer.  However, the medications used to reduce androgen in patients with advanced prostate cancer cause significant secondary illness.  Dr. Smith and his US/Canada team of investigators plan to study the health consequences of androgen reduction and will determine medical interventions to prevent the negative consequences of treatment.  This expert team will determine how to limit obesity, diabetes, bone fractures, and heart disease in patients treated for advanced prostate cancer.  Exercise, nutrition, and new medications will be employed to enhance the health of these patients with advanced prostate cancer.